论文部分内容阅读
目的:探讨胸腺肽α1辅助治疗2型糖尿病合并侵袭性肺曲霉菌病(IPA)患者的疗效及安全性.方法:50例2型糖尿病合并IPA患者随机分为观察组和对照组,对照组患者给予胰岛素降糖和伏立康唑抗曲霉菌治疗,疗程6～12周;观察组在此基础上给予胸腺肽α11.6mg.d-1皮下注射,疗程4周.观察两组临床疗效及治疗前后CD3+、CD4+、CD8+、CD4+/CD8+水平变化.结果:观察组治愈率明显高于对照组(P＜0.05).治疗后观察组CD3+、CD4+、CD4+/CD8+较前明显升高,CD8+则较前明显降低(P＜0.05);且与对照组比较差异有统计学意义(P＜0.05).结论:在IPA合并糖尿病的临床治疗上,除进行抢先抗真菌治疗外,提高免疫功能可明显提高临床疗效.“,”Objective:To investigate the clinical efficacy and safety of thymosin α1 in the treatment of type 2 diabetes mellitus (T2DM) with invasive pulmonary aspergillosis (IPA).Methods:Totally 50 cases of T2DM with IPA were randomly divided into the control group and the observation group.The routine treatment including insulin and voriconazole anti-fungal was carried out in the both groups for 6-12 weeks while the patients in the observation group were treated with thymosin α1,1.6 mg · d-1,subcutaneons injection for 4 weeks additionally.The clinical efficacy and the level of CD3 +,CD4 +,CD8 +,CD4 +/CD8 + were detected before and after treatment in the two groups.Results:The recovery rate of the observation group was significantly higher than the control group (P ＜ 0.05).The values of CD3 +,CD4 + and CD4 + /CD8 + were significantly increased,while the values of CD8 + was decreased significantly than before (P ＜ 0.05).The difference was statistically significant when compared with the control group (P ＜ 0.05).Conclusion:Increasing immune function besides antifungal treatment could significantly improve the clinical efficacy of T2DM patients with IPA.